Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Libertas Bio
US
- Ownership
- Private
- Development stage
- Other
01
Overview
Libertas Bio’s pipeline includes global rights to gusacitinib, an oral dual JAK/SYK inhibitor that is Phase 3-ready for chronic hand eczema and potentially other dermatological indications. The company also develops ASN008, a topical sodium channel blocker currently in a randomized double-blind Phase 2 trial for pruritus associated with atopic dermatitis. No published pivotal data yet; both programs are actively enrolling or preparing for late-stage trials as of mid/late 2024
- Therapeutic areas
- Dermatology
- Modalities
- Small molecules (e.g., gusacitinib, a dual JAK/SYK inhibitor)Topical sodium channel blockers (e.g., ASN008)
- Industry
- Biotech
02
Partnerships
No major pharmaceutical or biotech partnerships publicly disclosed.
Beyond the preview
Go deeper on Libertas Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Libertas Bio.